CDK8/19-IN-2
CDK8/19-IN-2 (compound 12) is an orally active and potent cyclin-dependent kinase 8/19 (CDK8 and CDK19) inhibitor, with IC50 values of 2.08 and 2.49 nM, respectively. CDK8/19-IN-2 can be used for acute myeloid leukemia (AML), breast cancer, and lymphoma research[1].
Product Specifications
CAS Number
[3024381-54-9]
UNSPSC
12352005
Target
CDK; STAT
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; JAK/STAT Signaling; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk8-19-in-2.html
Smiles
BrC1=C(C=C2N(C(N3CCNCC3)=NC2=C1C(F)F)C4CCOCC4)Br
Molecular Formula
C17H20Br2F2N4O
Molecular Weight
494.17
References & Citations
[1]Xu J, et al. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer. J Med Chem. 2024 May 23;67 (10) :8161-8171.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK19; CDK8
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items